Anixa reports final Phase 1 breast cancer vaccine data: 74% immune response, safe, advancing to Phase 2

Anixa Biosciences Inc

Vaccine met all primary endpoints; 74% of participants showed protocol-defined aLA-specific T cell responses.
Well tolerated at max tolerated dose; main adverse event was injection-site irritation; no flu-like symptoms.
Combination with Keytruda generated T cell responses without major additional side effects.
Enrolled 35 participants across three cohorts: early-stage TNBC, preventive mastectomy, adjuvant Keytruda.
Planning Phase 2 neoadjuvant combination study with Keytruda in newly diagnosed breast cancer patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.